Navigation Links
Viron to Present Data from Phase II Trial at American Heart Association Conference

LONDON, ON, Nov. 11 /PRNewswire/ - Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

The presentation entitled, "Viral Anti-inflammatory Treatment of Unstable Coronary Syndromes: The VT-111 Acute Coronary Syndrome Trial," will disclose recent results from a Phase IIa trial evaluating VT-111, a serine protein inhibitor, in patients with Acute Coronary Syndromes receiving coronary stents. Dr. Tardif's presentation is scheduled for Wednesday, November 18, 2009, at 11:00 AM (ET) in Room W304gh of the Orange County Convention Center. A copy of the presentation will be available after the conference on Viron's website,

About VT-111

VT-111, an immune-modulating protein therapeutic, is the world's first viral-derived human therapeutic. It is a novel inhibitor of the monocyte/macrophage influx to sites of injury and has demonstrated potent efficacy in preclinical models of acute injury in which inflammation plays a key role. VT-111 recently completed a Phase IIa trial of 48 patients with Acute Coronary Syndromes receiving coronary stents. In addition to advancing the cardiovascular program with a partner, Viron is moving to conduct appropriate preclinical studies prior to a clinical program to evaluate the effects of VT-111 in solid organ transplantation.

About Viron Therapeutics Inc. (

Viron is a biopharmaceutical company pioneering the development of pathogen proteins, a revolutionary new class of drugs. These drugs leverage strategies evolved by pathogens to inactivate key targets in the human immune system. The Company's proprietary PROSPECT(TM) technology, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a platform for the discovery of new immune-modulating protein therapeutics. Its significant pipeline of products target critical pathways that have broad application to immune and inflammatory based diseases such as cardiovascular disease and rheumatoid arthritis. VT-111, the Company's lead compound, is in development to treat Acute Coronary Syndromes and solid organ transplant rejection.

SOURCE Viron Therapeutics Inc.

SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders
2. RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products
3. The future of electricity may be found in environmentally friendly, thermoelectric cells
4. The future of electricity may be found in environmentally-friendly, thermoelectric cells
5. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
6. Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering
7. Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar
8. Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation
9. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
10. Hidden diversity in key environmental cleanup microbes found by systems biology assessment
11. How mercury becomes toxic in the environment
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ; ... up through cost cuts of priority ... based anywhere in the world will have the right to make, use and distribute ... where licensees based anywhere in the world will have the right to make, use ...
(Date:11/30/2015)... 2015 Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... designed to create shareholder value. ... "Based on published reports, the total addressable market ... and Spherix will seek to secure fair and ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
Breaking Biology News(10 mins):